Full TRIUMPH-2 Retatrutide Results Published in The Lancet, Presented at EASD 2026

Eli Lilly and Company said on September 29, 2026 that complete results from TRIUMPH-2, a Phase 3 trial of its investigational triple hormone receptor agonist retatrutide, were simultaneously published in The Lancet and presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. Lilly first disclosed topline weight-loss and A1C figures from TRIUMPH-2 in a July 23, 2026 corporate announcement; the September 29 release is the trial's first full peer-reviewed publication and its first complete public presentation, including safety and subgroup detail not included in the July announcement.

TRIUMPH-2 (ClinicalTrials.gov identifier NCT05929079) is an 80-week, randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 1,152 adults with type 2 diabetes and obesity or overweight, randomized to once-weekly retatrutide at 4 mg, 9 mg or 12 mg, or placebo. Participants entered the trial with an average body weight of 106.4 kg (234.6 lbs) and BMI of 38.2 kg/m2, and an average A1C of 7.7%.

Under the efficacy estimand, average weight loss at 80 weeks was 12.7% (29.8 lbs) at 4 mg, 19.1% (45.4 lbs) at 9 mg and 20.8% (49.6 lbs) at 12 mg, compared with 4.0% (9.3 lbs) on placebo. Among participants with a baseline BMI of 35 or higher, those on the 12 mg dose lost an average of 23.4% of body weight (60.8 lbs), and by the end of the study 59.5% of the 12 mg group no longer met the BMI criteria for obesity. The proportion of participants losing at least 20% of body weight was 24.0%, 45.3% and 52.0% across the three ascending doses, versus 1.5% on placebo.

A1C fell by an average of 1.4, 1.6 and 1.5 percentage points at the 4 mg, 9 mg and 12 mg doses, respectively, versus 0.2 points on placebo. Up to 40.0% of participants on retatrutide reached an A1C below 5.7%, a level Lilly's release described as within the normal range, compared with 4.4% on placebo. At the highest dose, retatrutide was also associated with average reductions of 39.5% in triglycerides, 19.6% in non-HDL cholesterol, 10.8 mmHg in systolic blood pressure and 58.3% in high-sensitivity C-reactive protein, relative to baseline. "In TRIUMPH-2, retatrutide reduced both weight and blood sugar substantially, with more than half of participants no longer qualifying as having obesity and up to 40% reaching an A1C in the normal range," said Juan P. Frías, M.D., the trial's principal investigator and medical director of the Los Angeles Institute for Metabolic Research, in Lilly's announcement.

The most common adverse events with retatrutide were gastrointestinal: diarrhea affected 27.4% to 33.6% of participants across doses versus 13.2% on placebo, nausea 13.7% to 28.0% versus 8.0%, constipation 14.0% to 16.8% versus 9.4%, and vomiting 5.5% to 15.7% versus 4.2%. Dysesthesia, a sensation of numbness or tingling, occurred in 4.5% to 7.3% of participants on retatrutide versus 0.7% on placebo. Lilly's release described these events as generally mild to moderate, with most resolving during treatment. Discontinuations due to adverse events ranged from 3.8% to 11.6% across the three retatrutide doses, compared with 4.9% on placebo.

Retatrutide remains investigational and has not been approved by the FDA, the European Medicines Agency or any other regulator. Lilly said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027, and that additional results from an obstructive sleep apnea sub-study within TRIUMPH-2 will be presented at a future medical meeting and published separately. This report describes clinical trial results and is not treatment or dosing guidance.